ProductUpdated on 28 April 2026
Nanobody-based biologics
About
NanoVet develops nanobody-based biologics for veterinary therapeutics, with a pipeline focused on high-burden chronic diseases, including canine atopic dermatitis, osteoarthritis, cancer immunotherapy and otherrs. Our platform leverages the unique properties of VHH antibodies, including high stability, strong tissue penetration, and cost-efficient manufacturing, enabling differentiated approaches compared to monoclonal antibodies, including multi-specific designs and alternative delivery strategies
Similar opportunities
Expertise
Nanobody engineering and translational biologics development
Nicolás Galmarini
CEO & Co-founder at NanoVet Biotech
Pamplona, Spain
Investment
Accelerate preclinical and clinical development
Nicolás Galmarini
CEO & Co-founder at NanoVet Biotech
Pamplona, Spain
Partnership
With Animal Health and Biotech companies
Nicolás Galmarini
CEO & Co-founder at NanoVet Biotech
Pamplona, Spain